1017 related articles for article (PubMed ID: 21955098)
1. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
9. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
[TBL] [Abstract][Full Text] [Related]
11. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
13. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
14. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
Scanlon JV; Exter BP; Steinberg M; Jarvis CI
Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
Zhu X; Zheng M; Song M; Shen YK; Chan D; Szapary PO; Wang B;
J Drugs Dermatol; 2013 Feb; 12(2):166-74. PubMed ID: 23377389
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
19. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
